Consequently, several monoclonal antibodies that block Ang2 are currently in clinical trials for conditions from acute respiratory distress syndrome induced by COVID-19 to diabetic eye disease (7, 8). Here, ANGPT2 is linked to acute respiratory distress syndrome.